After establishing clinical proof-of-concept with the prototype drug, final objectives of our drug discovery program included the following: optimize target inhibition; reduce possible side effects; ensure global patentability of novel derivatives. We altered the target profile for enzyme inhibition by ensuring immediate onset of action against both targets. Final leads required in vivo pharmacokinetics to enable once-per-day oral dosing in patients. Lastly, we determined drug profiles for NASH and gout that yielded characteristics specific to each illness. Each of these objectives was achieved, and Relburn is proceeding with late-stage testing to enable initiation of clinical trials.